Resource Library

biomarker discovery services partner

Sapient Extends Multi-Omics Services with High Throughput Discovery Proteomics

These services enable measure of thousands of proteins in blood and tissue across diverse biological pathways.

Dynamic biomarkers to optimize bioprocessing: scale up cell line productivity

How discovery mass spectrometry can be used to identify biomarkers to analyze, monitor & optimize bioprocessing workflows.

OMG OMx Podcast: A Conversation on All Things Omics with Dr. Tanya Nguyen

Dr. Nguyen joins Bruker's Kate Stumpo for a wide-ranging conversation on her experiences in the field of omics.

Bioanalysis Zone Feature: “Discovery technologies for the multi-omics era of precision medicine”

Sapient's Dr. Mo Jain discusses the role next-generation mass spectrometry will play in the evolution of precision drug development.

Sapient Multi-Omics Biomarker Discovery Services

See how we deliver bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis.

Discovery Metabolomics & Lipidomics Fact Sheet

See how we capture >15K small molecule biomarkers per biosample in a single run, across thousands of samples.

Discovery Proteomics Fact Sheet

See how our methods enable deep coverage of the blood & tissue proteome, and are scalable to your throughput needs.

Advancing Population Health insights with the addition of dynamic biomarkers

Population health studies finally have an efficient, scalable approach to ‘go beyond the genome’ in biomarker discovery.

Join us at Biomarkers UK 2024

Sapient will be attending and presenting at Europe’s flagship event for biomarker research. See where you can meet us.

Talk to Your Pharmacist Podcast: Success Occurs in the Margins with Nontargeted Discovery

Dr. Jain shares how nontargeted biomarker discovery provides a nontraditional path to advance drug development.

Discovery through data transparency: at the heart of scientific collaboration

Why data transparency is imperative to ensure the accuracy and reproducibility of findings that inform drug development.

How deep immune phenotyping via small molecule biomarkers could change the way we diagnose and treat autoimmune diseases

How small molecule biomarkers can help decipher autoimmune disease dynamics and inform drug development strategies.

Target Metabolite Panels and Lipid Panels for Focused Biomarker Discovery

See how Sapient enables focused biomarker discovery analyses with rapid time-to-insight.

Sapient Launches Target Metabolite and Lipid Panels for Focused Biomarker Discovery Analyses with Rapid Time-to-Insight

These ready-to-order panels speed time-to-insight through targeted exploration of known molecules.

Bioinformatics CRO Podcast: On novel biomarker discovery technologies

A discussion at the intersection of high throughput biomarker profiling, advanced data analytics, and biological insight.

Dynamic Biomarkers for Deep Immune Phenotyping in Autoimmune Disease

Now available on demand! Explore how small molecule biomarkers can drive greater understanding of autoimmune diseases.

Discovery of TE & PD biomarkers to advance antibody-drug conjugate (ADC) development

Explore how dynamic biomarkers of target engagement and PD can help decipher the heterogeneity of ADCs and their targets.

Discovery of a Biomarker of Biological Processes for Rare Disease

This case study details the discovery of a biomarker of biological processes in patients with sequence-verified mitochondrial disease.

Cell & Gene Therapy Optimization, a Framework: Assessing efficacy and safety with dynamic biomarkers

Now available on demand! Explore the applications for small molecule biomarkers in cell & gene therapy development.

The Future Is Now: Authority Magazine Interview with Sapient’s Jeramie Watrous

“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached…

Futurati Podcast: Biomarkers and personalized medicine

“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated…

Discovery of a PD Biomarker to Predict Drug Response

The inherent heterogeneity in patient populations can often lead to variable drug response. We recently worked with a client who…

Analytical Methods from Discovery to Diagnostic Development

Learn how we perform discovery screenings and then can translate key identified biomarkers into clinical assays.

Sapient’s High Complexity CLIA Laboratory Receives Accreditation from the College of American Pathologists (CAP)

August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis,…

Discovery of PD-1 Pathway Biomarkers of Target Engagement

The PD-1 pathway has transformed the development of immunotherapies as a means to reawaken the immune system to target cancer…

“Live from the Lab” at Sapient: On-Demand Virtual Lab Tour with Bruker

Watch the Livestream Recording | Presented by Bruker Watch the full recording of our recent lab tour showing how Sapient’s next-generation, ultra-high…

Nature Webinar | Beyond the genome: small-molecule biomarkers drive new advances in drug discovery

Now On Demand | Hosted by Nature Research Watch Now Human disease is a highly dynamic process. While next-generation genomic sequencing has…

Discovery of an Early Diagnostic Biomarker for NASH

The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) continue to rise worldwide, estimated to affect over one-quarter of…

VibeCast Podcast: Are Biomarkers the Future?

“Diagnostics have evolved tremendously. You could argue that the greatest benefit in human survival has come over the last 50…

How metabolomics can enrich preclinical safety studies

Preclinical safety assessments play a pivotal role in mitigating risk to enhance drug development success. Early identification of toxicological effects…

“Beyond Biotech” Podcast: A look at metabolite biomarkers with Sapient

“My hope is that in the very near future, in the next decade, an individual would go to a doctor’s…

Biocom LifeLines Magazine Feature: “Illuminating unknowns in the dynamic interplay of genetics, environment, and disease”

Biocom California recently asked Sapient to contribute an article for its Lifelines Magazine, a forum sharing insights and innovations that are leading…

Experts On… Biomarker Translation of Discoveries in Blood to Other Matrices

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Small Molecule Biomarkers + Adaptive Clinical Trials: Optimize Dosing & Timing of Treatments

Adaptive clinical trial designs are an emerging approach that bring flexibility to traditional linear study designs by adding a “review,…

Experts On… Translating Biomarker Discoveries into Real-World Assays

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Human Biology Database to Amplify Biomarker Discovery & Accelerate Validation

See how this database of data from 100,000+ biosamples enables rapid biomarker discovery & cross-validation.

Timing is Everything: Biomarkers for Early Detection of Preclinical Toxicology Events

Now On Demand | Hosted by AAPS Small molecule biomarkers represent dynamic indicators of adverse effects in the setting of drug exposure…

High-Throughput Biomarker Discovery for Clinical Trial Optimization

Now On Demand | Hosted by Oxford Global Advances in mass spectrometry resolution and sensitivity have enabled increasingly comprehensive views into the…

Reconstructing the landscape of gut microbial species across 29,000 diverse individuals

There is increasing evidence of the human gut microbiome’s link to health and disease. Exploring the composition and function of…

“Lab to Launch” Podcast: Enabling the next generation of biomarker discovery with Dr. Mo Jain

If you look at the data, the best drugs work in only 50% of people. Sapient’s Founder and CEO, Dr. Mo…

The Right Treatment, the Right Time: Biomarker-Guided Assessment of Clinical Trial Dynamics

Adaptive clinical trial designs seek to add flexibility to the fixed, linear “design-conduct-analyze” sequence of conventional clinic trials. Instead of assessing…

Technology Networks Feature: “Probing the Biomarker Landscape of Human Disease”

Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker…

Experts On… Delivering Value to Biopharma Sponsors

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Sapient Featured in Biocompare Article, “Mass Spectrometry for Biomarker Discovery”

Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes…

Experts On… The Impact of Chemical Discovery at Scale

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

The Clinical Trial Conundrum: Identifying Responders vs. Non-Responders

Now On Demand | Hosted by AAPS Will a patient respond or not respond to the given therapy? That is the fundamental…

Experts On… Making Biomarker Discoveries Actionable

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Mapping Metabolic Changes for Diabetes Prediction with Machine Learning

Understanding the risk factors that give rise to human disease is essential to early detection and development of effective treatments…

Experts On… Multi-Omics Data Integration

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Chemistries & Methods: How We Achieve Breadth and Depth in Chemical Discovery

There are tens of thousands of unknown molecules circulating in human blood – thousands of which could represent robust biomarkers.…

Experts On… Machine Learning in Biomarker Discovery

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Experts On… Approaching Experimental Design

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Thinking outside the brain to advance CNS drug development

CNS diseases can have a wide range of symptoms which can make them difficult to diagnose and treat based on…

Experts On… Defining Biocomputational Approaches

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…

Untargeted Lipidomics Services for an Unprecedented Scale of Biomarker Discovery

Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human lipidome at a rate that is unmatched…

Fierce Webinar: Population-Scale Circulating Biomarker Discovery to Accelerate Drug Development

Now On Demand | Hosted by Fierce Pharma Watch Now In this session, Sapient discusses application of its next-generation mass…

Be More Specific: Solving the Specificity Challenge in Metabolomics

Disease processes are complex. Individuals with the same genetic disorder, symptoms, and/or diagnosis can have varied prognosis and response to…

Advances in Proteomics & Metabolomics 2022 Online Symposium

Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling Now On Demand | Presented by Technology…

SLAS New Matter Podcast: A Conversation on Small Molecule Biomarkers with Dr. Mo Jain

Dr. Jain also shares his background and what led to him to creating Sapient along with the company’s own next-generation…

What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Disease Prediction, Diagnostics and Therapies

Now On Demand | Hosted by AAPS Watch Now While next-generation sequencing has been instrumental in advancing genomics-based precision medicine,…

Fierce Pharma Feature: Small molecule biomarkers to align patients, disease, and therapy

Sapient recently contributed a piece to Fierce Pharma discussing the new biological and disease insights that small molecule biomarkers can…

University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics

September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes…

Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19

Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital…

Mapping the Missing Link: Bridging the Gap Between Human Genetics and Disease Biology Through Small Molecule Biomarker Discovery

Now On Demand | Hosted by AAPS Watch Now Genome-wide association studies (GWAS) have been transformative in elucidating the genetic…

Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis

The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention,…

Genomic + Small Molecule Biomarkers: for a More Complete Picture of Disease Risk

An individual’s phenotype is not dictated solely by their genetic variants. Environmental factors – where we live, what we eat,…

Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022

“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and…

Data ≠ Insight: Improving Metabolomics Data Interpretation

Untargeted biomarker discovery aims to uncover previously unknown factors that associate with biologically relevant changes in human health and disease,…

Identifying Non-Invasive Biomarkers of Target Engagement

Now On Demand | Hosted by AAPS Watch Now A key aspect of the drug discovery pipeline is evaluation of in…

On the Mark? Identifying Biomarkers of Target Engagement

Retrospective analyses conducted by major pharmaceutical companies on their drug pipelines have revealed that close to one-fifth of Phase II failures due…

What is Discovery at Scale? Multiplying the Rate of Nontargeted Biomarker Profiling

A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to…

Smaller, Faster & More Effective: Clinical Trial Enrichment Using Circulating Biomarkers

Now On Demand | Hosted by AAPS Watch Now Diseases are singularly defined but often represent varied groupings of contributing factors…

Harnessing the Human Microbiome for Discovery

Learn about RExMap and our methods to advance biomarker-based discovery of microbially derived metabolites.

Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium

San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for…

Comparison of Omics Techniques and Biomarker Types

High throughput technologies can now capture and measure a huge number of biological molecules within a single human cell or…

Discovery of Biomarker to Predict Immunotherapy Related Autoimmunity

Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While…

Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery

Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for…

Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report

San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area…

Platform Explainer: How Sapient Accelerates Biomarker Discovery

At Sapient, we believe biomarker-driven drug development can transform lives – and accelerate the process at a fraction of the…

Biomarker-Driven Clinical Trials: Enriched with Biology, Evolved for a New Era

Why are large, expensive clinical trials so common? It stems from the challenge of needing to demonstrate treatment efficacy in…

Large Scale Biomarker Discovery: Next-Gen Mass Spectrometry Profiling to Accelerate Drug Development

Now On Demand | Hosted by AAPS Circulating biomarker discovery is a critical component of the drug discovery process, identifying markers…

Getting Drug Development Right

The omics revolution has enabled many breakthroughs in our understanding of disease biology, but the productivity of clinical drug development…

Deep Neural Networks for Classification of LC-MS Spectral Peaks

Nontargeted LC-MS can assay thousands of chemical entities in a single biospecimen, but in that crush of data, how do…